Genetic depletion of adipose-derived Isthmin-1 causes hepatic steatosis

Genetic depletion of adipose-derived Isthmin-1 causes hepatic steatosis

Objectives: Adipose tissue plays a critical role in obesity, as its dysfunction can impair lipid homeostasis and result in lipid overflow and ectopic lipid deposition in the liver. We previously demonstrated that Isthmin-1 (Ism1) regulates glucose uptake into the adipose tissue and suppresses hepati...

Full description

Saved in:

Bibliographic Details
Main Authors:	Saranya C. Reghupaty, Laetitia Coassolo, Meng Zhao, Ramya Lakshmi Narasimhan, Aayan Patel, Jameel Lone, Ewa Bielczyk-Maczynska, Niels B. Danneskiold-Samsoee, Taylor Brown, Zewen Jiang, Veronica L. Li, Katrin J. Svensson
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Molecular Metabolism
Subjects:	Adiposity Metabolic-dysfunction associated steatotic liver disease (MASLD) Metabolic-dysfunction associated steatohepatitis (MASH) Isthmin-1 (Ism1) Lipidomics
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212877825000791
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Chronic administration of a cannabis-derived mixture at an antihyperalgesic dose does not significantly enhance hepatotoxicity or the development of metabolic dysfunction-associated steatohepatitis in male mice
by: Kim B. Pedersen, et al.
Published: (2025-05-01)

Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis
by: Barbora Nováková, et al.
Published: (2025-08-01)

Machine Learning-Based Non-Invasive Prediction of Metabolic Dysfunction-Associated Steatohepatitis in Obese Patients: A Retrospective Study
by: Jie Chen, et al.
Published: (2025-04-01)

Serum Isthmin-1 levels are positively correlated with macrovascular complications in type 2 diabetic patients
by: Yajing Wang, et al.
Published: (2025-06-01)

Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
by: Yi-Tong Li, et al.
Published: (2025-04-01)

Metallothionein 1B attenuates inflammation and hepatic steatosis in MASH by inhibiting the AKT/PI3K pathway
by: Canghai Guan, et al.
Published: (2025-01-01)

Combination Therapy of Half-Dose Resmetirom and Metformin Attenuates Metabolic Dysfunction-Associated Steatohepatitis Through Improving Cholesterol Metabolism and Inflammation
by: Wenxiu Liu, et al.
Published: (2025-05-01)

Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning
by: Ying Geng, et al.
Published: (2024-11-01)

Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
by: Nahee Hwang, et al.
Published: (2025-04-01)

A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S.
by: Shyam Patel, et al.
Published: (2025-01-01)

Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma
by: Evangelia E. Tsakiridis, et al.
Published: (2025-05-01)

Macrophage‐Hepatocyte Circuits Mediated by Grancalcin Aggravate the Progression of Metabolic Dysfunction Associated Steatohepatitis
by: Tian Su, et al.
Published: (2024-11-01)

Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances
by: Caesar Ferrari, et al.
Published: (2024-10-01)

Metformin Increases Serum Isthmin-1 Levels and Lowers Low-Density Lipoprotein: Potential Implications for Lipid Metabolism in T2DM
by: Merve Yilmaz Bozoglan, et al.
Published: (2025-03-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Isthmin1 Upregulation in the Intestinal Microenvironment During <i>Salmonella</i> Typhimurium Infection: Identification and Characterization of Isthmin1-Producing Cells
by: Gustavo Alberto Jaimes-Ortega, et al.
Published: (2025-05-01)

Crosstalk between Epigenetics and Autophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Irfana Zahoor, et al.
Published: (2025-07-01)

HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
by: Vincent Wai-Sun Wong, et al.
Published: (2025-07-01)

TREM2 in MASH: integrating lipid metabolism and immune response
by: Shuyi Shi, et al.
Published: (2025-06-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Alnustone Ameliorates Metabolic Dysfunction‐Associated Steatotic Liver Disease by Facilitating Mitochondrial Fatty Acid β‐Oxidation via Targeting Calmodulin
by: Shourui Hu, et al.
Published: (2025-08-01)

The Association Between Serum Isthmin-1 and Disease Activity, Inflammation, and Autoantibody Status in Rheumatoid Arthritis
by: Burak Oz, et al.
Published: (2025-05-01)

Identification of Glycolysis-Related Genes in MAFLD and Their Immune Infiltration Implications: A Multi-Omics Analysis with Experimental Validation
by: Jiawei Chen, et al.
Published: (2025-07-01)

Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials
by: Samuel Dinerman, et al.
Published: (2025-01-01)

Advances in non-invasive diagnosis of metabolic dysfunction-associated fatty liver disease
by: WANG Ziqian, et al.
Published: (2024-07-01)

RENAL INJURY AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH OBESITY
by: Kellyane Dias CARVALHO, et al.
Published: (2025-05-01)

Gelsolin's Protective Role in MASH through F‐Actin Regulation and P53 Degradation
by: Yiwei Lu, et al.
Published: (2025-06-01)

Expression changes and functional role of GPR110 in metabolic dysfunction-associated steatohepatitis
by: Ting HONG, et al.
Published: (2025-06-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Association of Index and Changes in Fibrosis-4 Score With Outcomes in Metabolic Dysfunction-Associated Steatohepatitis
by: Semiu O. Gbadamosi, et al.
Published: (2025-01-01)

Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050
by: Jincheng Tang, et al.
Published: (2025-07-01)

Development of a novel diagnostic model to monitor the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma in females
by: Xiaoning Gan, et al.
Published: (2024-12-01)

Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer
by: Patrick Huang, et al.
Published: (2025-05-01)

MicroRNA-26b protects against MASH development in mice and can be efficiently targeted with lipid nanoparticles
by: Linsey Peters, et al.
Published: (2025-04-01)

Small intestinal bacterial overgrowth and metabolic dysfunction-associated steatotic liver disease
by: Ziteng Wang, et al.
Published: (2024-12-01)

Editorial: Unraveling the links between nutrients and metabolic dysfunction-associated liver disease: insights and implications
by: Bruno Ramos-Molina, et al.
Published: (2024-11-01)

Steatotic Liver Disease Education Enhances Knowledge and Confidence to Adhere to Provider Recommendations in Diverse and Vulnerable Populations
by: Shyam Patel, et al.
Published: (2025-01-01)

Association of estimated glucose disposal rate with risk of future metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases: a prospective cohort study
by: Yan Li, et al.
Published: (2025-07-01)

Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
by: Yoon-su Ha, et al.
Published: (2025-04-01)

Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
by: Yoon-su Ha, et al.
Published: (2025-04-01)